Radiation therapy in borderline resectable pancreatic cancer: A review

被引:4
|
作者
Turner, Kevin M. [1 ]
Delman, Aaron M. [1 ]
Kharofa, Jordan R. [2 ]
Smith, Milton T. [3 ]
Choe, Kyuran A. [4 ]
Olowokure, Olugbenga [5 ]
Wilson, Gregory C. [1 ,6 ]
Patel, Sameer H. [1 ,6 ]
Sohal, Davendra [5 ]
Ahmad, Syed A. [1 ,6 ,7 ]
机构
[1] Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH USA
[2] Univ Cincinnati, Dept Radiat Oncol, Coll Med, Cincinnati, OH USA
[3] Univ Cincinnati, Dept Internal Med, Div Digest Dis, Coll Med, Cincinnati, OH USA
[4] Univ Cincinnati, Dept Radiol, Coll Med, Cincinnati, OH USA
[5] Univ Cincinnati, Dept Internal Med, Div Hematol & Oncol, Coll Med, Cincinnati, OH USA
[6] Univ Cincinnati, Dept Surg, Div Surg Oncol, Coll Med, Cincinnati, OH USA
[7] Univ Cincinnati, Chief Div Surg Oncol, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA
关键词
PHASE-II TRIAL; INTENSITY-MODULATED RADIOTHERAPY; NEOADJUVANT THERAPY; DUCTAL ADENOCARCINOMA; PREOPERATIVE CHEMORADIATION; OPEN-LABEL; GEMCITABINE; CHEMOTHERAPY; CHEMORADIOTHERAPY; RESECTION;
D O I
10.1016/j.surg.2021.12.013
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Borderline resectable pancreatic cancer constitutes a complex clinical entity, presenting the clinician with a locally aggressive disease that has a proclivity for distant spread. The benefits of radiation therapy, such as improved local control and improved survival, have been questioned. In this review we seek to summarize the existing evidence on radiation therapy in borderline resectable pancreatic cancer and highlight future areas of research. Methods: A comprehensive review of PubMed for clinical studies reporting outcomes in borderline resectable pancreatic cancer was performed in June 2021, with an emphasis placed on prospective studies.Results: Radiologic "downstaging" in borderline resectable pancreatic cancer is a rare event, although some evidence shows increased clinical response to neoadjuvant chemotherapy over radiation therapy. Margin status seems to be equivalent between regimens that use neoadjuvant chemotherapy alone and regimens that include neoadjuvant radiation therapy. Local control in borderline resectable pancreatic cancer is likely improved with radiation therapy; however, the benefit of improved local control in a disease marked by systemic failure has been questioned. Although some studies have shown improved survival with radiation therapy, differences in the delivery and tolerance of chemotherapy between the neoadjuvant and adjuvant setting confound these results. When the evidence is evaluated as a whole, there is no clear survival benefit of radiation therapy in borderline resectable pancreatic cancer.Conclusion: Once considered a staple of therapy, the role of radiation therapy in borderline resectable pancreatic cancer is evolving as systemic therapy regimens continues to improve. Increased clinical understanding of disease phenotype and response are needed to accurately tailor therapy for individual patients and to improve outcomes in this complex patient population. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [1] Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer
    Kumar, Rachit
    Jabbour, Salma K.
    [J]. JOURNAL OF RADIATION ONCOLOGY, 2013, 2 (04) : 353 - 367
  • [2] Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
    Lee, Sang Hoon
    [J]. KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 84 (03): : 103 - 110
  • [3] Neoadjuvant Chemoradiation With Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (PCa)
    Kharofa, J. R.
    Kelly, T.
    Wood, C.
    George, B.
    Tsai, S.
    Ritch, P.
    Wiebe, L.
    Christians, K.
    Evans, D.
    Erickson, B.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S89 - S89
  • [4] Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
    Barreto, Savio George
    Shrikhande, Shailesh, V
    Sirohi, Bhawna
    [J]. INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (SUPPL 2) : 249 - 254
  • [5] Strategy of Neoadjuvant Therapy for Resectable/Borderline Resectable Pancreatic Cancer
    Hashimoto, D.
    Satoi, S.
    Yamamoto, T.
    Yamaki, S.
    Hirooka, S.
    Ishida, M.
    Ikeura, T.
    Sekimoto, M.
    [J]. PANCREAS, 2021, 50 (07) : 1064 - 1064
  • [6] Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review
    Endo, Yutaka
    Kitago, Minoru
    Kitagawa, Yuko
    [J]. CANCERS, 2024, 16 (09)
  • [7] Efficacy and feasibility of chemotherapy and radiation therapy for borderline resectable pancreatic cancer in elderly patients
    Figura, Nicholas
    Cruz, Alex
    Mellon, Eric Albert
    Chuong, Michael
    Hoffe, Sarah
    Springett, Gregory M.
    Saeed, Nadia
    Hodul, Pamela Joy
    Malafa, Mokenge Peter
    Balducci, Lodovico
    Shridhar, Ravi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [8] Borderline resectable pancreatic cancer
    Hackert, Thilo
    Ulrich, Alexis
    Buechler, Markus W.
    [J]. CANCER LETTERS, 2016, 375 (02) : 231 - 237
  • [9] Borderline resectable pancreatic cancer
    Varadhachary G.R.
    Tamm E.P.
    Crane C.
    Evans D.B.
    Wolff R.A.
    [J]. Current Treatment Options in Gastroenterology, 2005, 8 (5) : 377 - 384
  • [10] Borderline Resectable Pancreatic Cancer
    Mullapudi B.
    Hawkes P.J.
    Patel A.
    Are C.
    Misra S.
    [J]. Indian Journal of Surgical Oncology, 2015, 6 (1) : 63 - 68